In this setting, anti-PlGF treatment prolonged survival of imatinib-sensitive and -resistant CML mice and added to the anti-CML activity of imatinib [88]. This evidence concerns the gene PGF and chronic myelogenous leukemia, BCR-ABL1 positive.